Vaccine Research Facilitated Rapid Response to Ebola Outbreak
Wednesday, May 26, 2021
IRP Senior Investigator Heinz Feldmann, M.D., was elected to the National Academy of Medicine (NAM) last year for leading the development of the technology that resulted in the first Ebola vaccine approved by the US Food and Drug Administration (FDA) and used by the World Health Organization (WHO) to combat the deadly disease. Election to the NAM is considered one of the highest honors in the fields of health and medicine.
As chief of the Laboratory of Virology at the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Feldmann’s work focuses on viruses like Ebola that cause hemorrhagic fever, a condition marked by fever, weakness, muscle pain, and sometimes bleeding. These highly contagious viruses require specialized laboratories and strict safety procedures to study.
Findings Point to Approaches for Staving Off Health Problems in Infected Individuals
Tuesday, April 27, 2021
Over the four decades since it mysteriously began destroying the immune systems of Americans in New York and California, HIV has proven to be a frustratingly wily opponent for scientists. Even today, when treatments can fully suppress the virus in infected individuals, it continues to harm their health. A new IRP study has identified several ways dormant HIV might chronically stimulate the immune system, suggesting potential avenues for preventing the health problems that causes.
IRP Researcher Nancy Sullivan Led Development of Cutting-Edge Treatment
Wednesday, February 10, 2021
Twenty-four years before the novel coronavirus began spreading in Wuhan, China, an outbreak of another deadly virus burned through the city of Kikwit in what is now the Democratic Republic of Congo. Between January and August of 1995, 316 people are thought to have contracted Ebola, and 252 of them died. More than a decade later, a team of NIH infectious disease scientists would track down one of the survivors and use a sample of the individual’s blood to produce one of the first effective treatments for Ebola.
NIH Researcher’s Pioneering Work Led to Discovery of Hepatitis C
Monday, January 11, 2021
When the phone rang at 4:15 in the morning, IRP senior scientist Harvey J. Alter, M.D., was annoyed. He didn’t answer it. After the third try, he reluctantly got out of bed and took his phone out to the hallway.
“Before I could yell at the person, he said, ‘This is Stockholm calling,’” Dr. Alter recalls. “And then I got stopped in my tracks. Then the moment of disbelief and awe comes over you.”
The man from Stockholm informed Dr. Alter that he had won the 2020 Nobel Prize in Physiology or Medicine for his contributions to the discovery of the hepatitis C virus. He shared the prize with Michael Houghton, Ph.D., of the University of Alberta, Canada, and Charles M. Rice, Ph.D., of Rockefeller University in New York.
IRP Leverages Supercomputing to Combat Coronavirus
Wednesday, August 19, 2020
Over the past six months, a tiny virus has completely upended life in the United States and many other countries. To combat this microscopic threat, some IRP researchers have turned to a tool the size of a small building.
Biowulf, the NIH’s supercomputer, is supporting more than a dozen different IRP research projects focused on the novel coronavirus. As the world’s most powerful supercomputer solely dedicated to biomedical research, Biowulf allows scientists to analyze data and run simulations at unprecedented speed. Two weeks ago, a blog post described how IRP investigators are using Biowulf to elucidate the structure of the novel coronavirus and simulate how potential therapeutics might interact with it. Picking up where that post left off, this blog will explore the application of Biowulf to important questions about the spread of COVID-19 and the way that its genes, along with our own, might influence its impact on the body.